Showing 5491-5500 of 7866 results for "".
- Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-shows-efficacy-adults-severe-alopecia-areata/2468485/New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningfu
- Positive Results for Guselkumab for Moderate PsO Patientshttps://practicaldermatology.com/news/positive-results-guselkumab-moderate-pso-patients/2468490/Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conferenc
- Details Revealed for Upcoming Phase 2 Study for New AD Drug from Apogeehttps://practicaldermatology.com/news/details-revealed-upcoming-phase-2-study-new-ad-drug-apogee/2468489/Apogee Therapeutics’ half-life-extended monoclonal antibody APG777 for atopic dermatitis was the subject of a poster presented by Dr. Emma Guttman-Yassky and others at the 44th Annual Fall Clinical Dermatology Conference. The poster detailed the design of the phase 2 APEX study. “IL
- Promising Pipeline for CSU Optionshttps://practicaldermatology.com/news/promising-pipeline-csu-options/2468488/Cleveland Clinic allergist Dr. David Lang joined Dr. Dawn Merritt and Dr. Brad P. Glick to discuss chronic spontaneous urticaria (CSU) at the 44th Annual Fall Clinical Dermatology Conference and noted that the future is very promising. “Our recent understanding of chronic urticaria has imp
- Analysis: Lebrikizumab Viable Dupilumab Alternative for Moderate-to-Severe ADhttps://practicaldermatology.com/news/analysis-lebrikizumab-viable-dupilumab-alternative-moderate-severe-ad/2468484/Lebrikizumab is a viable alternative for patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab due to inadequate response, inability to tolerate the drug, or other reasons, according to a new study presented at the Fall Clini
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- LEO Pharma Announced CHE Awareness Campaignhttps://practicaldermatology.com/news/leo-pharma-announced-che-awareness-campaign/2468442/LEO Pharma Inc. has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE)—a debilitating skin condition for which there are currently no FDA approved treatments. <
- READY-4: Sustained and Safety Efficacy of RelabotulinumtoxinAhttps://practicaldermatology.com/news/ready-4-sustained-and-safety-efficacy-relabotulinumtoxina/2468443/New results from the phase III READY-4 trial presented at the 2024 ASDS Annual Meeting demonstrate the long-term safety and sustained efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) for the treatment of moderate-to-severe frown lines and crow’s feet. The multicenter, open-label REA
- New Eczema Relief Balm Available From Avènehttps://practicaldermatology.com/news/new-eczema-relief-balm-available-avene/2468441/French skincare brand Avène introduced XeraCalm Eczema Calming Relief Balm and Cicalfate+ Intensive Skin Restoration Serum, two new innovations that feature the company’s mineral-rich Thermal Spring Water. “These breakthrough formulations are at the heart of how Eau Thermale Avène cares fo
- JOYA Launches Skin Cancer Prevention, Anti-Aging Employee Benefit Platformhttps://practicaldermatology.com/news/joya-launches-skin-cancer-prevention-anti-aging-employee-benefit-platform/2468435/JOYA, the first employee skin health and wellness benefit platform, announced its emergence from stealth mode with $5 million in seed funding from LUX Capital, Mosaic General Partnership, Arsama Trust, and Joyance Partners. The funding will support team expansion, product development, mar